The graft-versus-leukemia effect

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 89-95

  Barrett, John ^a   Malkovska, Vera ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; LEUKEMIA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY;

EID: 0029885562     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00003     Document Type: Review

References (69)

1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1991, 75:555-562.
2. Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringden O, Stone JAV, Bortin MM: Identical twin bone marrow transplants for leukemia. Ann Inter Med 1994, 120:646-652. The International Bone Marrow Transplant Registry database of over 120 syngeneic marrow transplants for leukemia was used to compare relapse rates with those of HLA-identical sibling BMT. The GVL effect of the allotransplant was quantitated and shown to be greatest for patients with CML, intermediate for acute myelogenous leukemia and least for acute lymphoblastic leukemia.
3. Korngold R, Leighton C, Manser T: Graft-versus-myeloid responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 1994, 15:278-287.
4. + T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 1995, 60:355-361.
5. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC compatible bone marrow. Bone Marrow Transplant 1991, 8:51-58.
6. Zeiss M, Uharek L, Glass B, Gaska T, Gassmann W, Muller-Ruchholz W: Induction of graft-versus-leukemia (GVL) activity in murine models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Bone Marrow Transplant 1994, 14:711-715.
7. OKunewick JP, Kociban DL, Machen LL, Buffo MJ: Evidence for a possible role of asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia. Bone Marrow Transplant 1995, 16:451-456. Evidence for a natural killer-mediated antileukemic effect contributing to allogeneic GVL in an MHC-matched mouse model. Natural killer cells may exert a strong alloresponse to virally transformed leukemias.
8. Weiss L, Reich S, Slavin S: The role of antibodies to IL-2 receptor and asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia. Bone Marrow Transplant 1995, 16:457-461. This study demonstrates the contribution of natural killer cells and interleukin-2 (and therefore possibly interleukin-2 activated natural killer cells) to a GVL effect against a B-cell leukemia in an MHC-mismatched murine transplant model.
9. Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S: Effective graft-versus-leukemia effects independent of graft-versus-host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma: role of cell therapy and IL-2. J Immunol 1994, 153:2562-2567.
10. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S: Enhancement of a GVL effect with rhlL-2 following BMT in a murine model for acute myeloid leukemia. Exp Hematol 1995, 23:196-201.
11. - mediated graft-versus-leukemia effects. Blood 1994, 82:2560-2569.
12. Aizawa S, Sado T, Kamiskau H, Nemoto K, Yoshida K: Graft-versus-leukemia in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias. Bone Marrow Transplant 1994, 13:109-114.
13. Malkovska V, Cigel F, Storer BE: Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumor immunity. Clin Exp Immunol 1994, 96:158-165.
14. Goulmy E: Minor histocompatibility antigens and their role in transplantation. Transplant Rev 1988, 2:29-53.
15. Wang W, Meadowa LR, den Haan JMM, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik AI, Hendrickson RC, Bishop CE, Hunt DF, Goulmy E, Engelhard V: Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995, 269:1588-1590. Molecular characterization of the minor histocompatibility antigen responsible for GVHD in female-to-male BMT.
16. den Haan JMM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfthout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard V, Goulmy E: Identification of a graft-versus-host disease-associated minor histocompatibility antigen. Science 1995, 268:1476-1479. Molecular characterization of a lymphoid/myeloid tissue-restricted minor antigen that could be used as a target for selective T-cell responses to leukemia cells and not GVHD target tissues.
17. de Bueger M, Bakker A, van Rood JJ, van der Woude F, Goulmy E: Tissue distribution of minor histocompatibility antigens. J Immunol 1992, 149:1788-1794.
18. Marijt WAF, Kernan NA, Diaz-Barrientos TH, Veenhof WFJ, O'Reilly RJ, Willemz R, Falkenberg JHF: Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA identical bone marrow transplantation. Bone Marrow Transplant 1995, 16:125-132.
19. van der Harst D, Goulmy E, Falkenberg JHF, Kooij-Winkelaar Y, van Luxemburg-Heijs S, Goselink HM, Brand A: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cell lines by cytotoxic T-cell clones. Blood 1994, 83:1060-1066.
20. Barrett AJ, Jiang YZ: Immune responses to chronic myeloid leukaemia: review. Bone Marrow Transplant 1992, 9:305-311.
21. + lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML/RARa present in acute promyelocytic cells. Blood 1993, 81:1369-1375.
22. Cullis J, Barrett AJ, Lechler R, Goldman JM: Binding of bcr/abl junctional peptides to MHC class I molecules: studies in antigen processing defective cell lines. Leukemia 1994, 8:165-170.
23. 1- cells from the same patient. Blood 1994, 83:3390-3402.
24. + helper cell stimulation, leading to an effective cytotoxic T-cell antileukemia response.
25. Delain M, Tiberghien P, Racadot E, Billot M, Pariste J, Chabod J, Cahn JY, Herve P: Variability of the alloreactive T-cell response to human leukemic blasts. Leukemia 1994, 8:642-647.
26. Faber LM, van Luxemburg-Heijs SA, Willemz R, Falkenberg JH: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identlcal bone marrow donor of a patient with leukemia. J Exp Med 1992, 176:1283-1289.
27. + cells were responsible for both GVL and GVHD reactivity.
28. Salomo M, Steinmann J, Glass B, Herwartz C, Uharek L, Gassmann W, Muller-Ruchholz W: Leukemia-specific allogeneic donor T cells: quantification by limiting dilution assay. Bone Marrow Transplant 1995, 15:179-186.
29. Jiang YZ, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barrett AJ: Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T-lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 1991, 8:253-258.
30. Hoffmann T, Theobald M, Bunjes D, Weiss M, Heimpel H, Heit W: Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 1993, 12:1-8.
31. + clones against leukemia colony-forming unit granulocyte macrophage was partly by direct cell-to-cell interaction and partly through cytokine production.
32. + T-cell depletion to achieve a low leukemia relapse rate and low incidence of severe GVHD in BMT for CML.
33. + T cells have a central role in the GVL effect against CML.
34. Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson KC, Murray C, Bohuon C, Ythier A, Ritz J: Characterization of natural killer cells with antileukemic activity following allogeneic bone marrow transplantation. Blood 1966, 67:722-730.
35. Kurago ZB, Smith KD, Lutz CT: NK cell recognition of MHC class I. J Immunol 1995, 153:2631-2641. This study provides new clues to the mechanism of allorecognition by natural killer cells. The findings suggest that natural killer alloreactivity against leukemia could be elicited more easily than natural killer responses to autologous leukemia.
36. Malnati MS, Peruzzi M, Parker KC, Biddeson WE, Ciccone E, Moretta A, Long EO: Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995, 267:1016-1018. A paper that sheds light on the poorly characterized interaction of natural killer cells with their targets. The study with Kurango et al. (J Immunol 1995, 153:2631-2641) provides new clues to the mechanism of allorecognition by natural killer cells. The findings suggest that natural killer alloreactivity against leukemia could be elicited more easily than natural killer responses to autologous leukemia.
37. Kagi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxiciy. Science 1994, 265:528-530. The demonstration in fas and perforin knockout mice that T cells mainly use only two pathways of cell-mediated cytotoxicity is a major advance in our understanding of the mechanisms of T-cell antileukemia responses.
38. Giralt SA, Champlin RE: Leukemic relapse after allogeneic bone marrow transplantation: a review. Blood 1994, 84:3603-3612.
39. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonk L, Niederwieser D, van Rhee F, Mittermuller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050. The largest cumulative experience of DLT to treat relapsed leukemia. Favorable responses of CML with sustained "molecular" cures and unsustained responses in acute myelogenous leukemia and acute lymphoblastic leukemia. The paper contains references to all the major reports of DLT for leukemia relapse after BMT.
40. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995, 345:9-13. Successful use of selected gene-marked T-cell lines with activity against Epstein-Barr virus to treat lymphoproliferative disease after allogeneic marrow transplantation.
41. Papadopoulos EB, Ladanyi M, Emmanuel D, Mackinnon S, Boulad F, Carabasi M, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusion of donor leukocytes to treat Epstein-Barr Virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
42. Mackinnon S, Papadopoulou EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs GB, Gillio A, Kernan NA, Small T, Young J, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myelogenous leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1270. This study of increasing doses of donor lymphocytes for relapsed CML determines the threshold number of donor lymphocytes necesary for response.
43. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard O, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar C, Hale G, Waldmann H, Steinberg SM, Slavin S: T-cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995, 89:506-515. Transplantation experience from a single BMT team describing T-cell depleted BMT followed by add-back of donor lymphocytes to treat high relapse risk leukemias. Low relapse rate and low incidence of acute GVHD indicates that this procedure can separate GVHD from GVL reactions.
44. Ferster A, Bujan W, Moreaux T, Devlack Ch, Heimann P, Sariban E: Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant 1994, 14:331-332.
45. Pati AR, Godder K, Lamb L, Gee A, Henslee-Downey JPJ: Immunotherapy with donor leukocyte infusions for patients with relapsed acute myelogenous leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995, 15:979-981. Complete but short-lived remission with severe acute GVHD following DLT for untreated acute myelogenous leukemia relapsing after BMT from a mismatched family donor.
46. Kloosterman TC, Tielemans MJC, Martens ACM, van Bekkum DW, Hagenbeek A: Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplatation in rat models for acute myelocytic and lymphocytic leukemia. Bone Marrow Transplant 1994, 14:5-22.
47. Shaffer L, Giralt S, Champlin R, Chan KW: Treatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2. Bone Marrow Transplant 1995, 15:317-319.
48. Browett PJ, Nelson J, Tiwati S, van de Water NS, May S, Palmer SJ: Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation. Bone Marrow Transplant 1994, 14:641-644.
49. Mehta J, Powles RL, Singhal S, Tait D, Sawnsbury J, Treleaven J: Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 16:133-138.
50. Goldberg SL, Mangan KF, Klumpp TR, Cropper TM, Schnall SF, Macdonald JS: Lack of a graft-versus-leukemia effect in an immunologically privileged sanctuary site. Bone Marrow Transplant 1993, 12:180-181.
51. Sackstein R: Physiologic migration of lymphocytes to lymph nodes following bone marrow transplantation: role in immune recovery. Semin Oncol 1993, 20:34-39.
52. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ: T-cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993, 11:133-138.
53. Aoki Y, Takahashi S, Okamoto S, Asano S: Graft-versus-leukemia after second allogeneic bone marrow transplantation [letter]. Blood 1994, 84:3981.
54. Miyamura K, Barrett AJ, Kodera Y, Saito H: Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results. Bone Marrow Transplant 1994, 14:201-209.
55. Marmont AM, Horowitz MM, Gale RP, Sobocinski KA, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong DR, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
56. Mckinnon S, Barnett L, Heller G, O'Reilly RJ: Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994, 83:3409-3416.
57. Thiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux J-M, Contassot E, Murphy WJ, Lyons R, Chiang Y, Herve P, Longo D, Ruscetti FW: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994, 84:1333-1341.
58. Antin JH, Ferrara JLM: Cytokine dysregulation and and acute graft-versus-host disease. Blood 1992, 80:2964-2970.
59. Johnson BD, Truitt RL: Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995, 85:3302-3312. Animal experiments that demonstrate that T-cell-depleted BMT followed by delayed T-cell add-back confer a GVL response, while donor-host tolerance is maintained. A model for clinical trials of T-cell depletion followed by T-cell addback.
60. Couriel D, Cottler-Fox M, Burt RK, Dunbar C, Hensel N, Young NS, Barrett AJ: T-cell depleted marrow transplants with delayed lymphocyte addback to prevent relapse in patients with leukemia and MDS. Blood 1994, 64(supp 1):334A.
61. Cavazzana-Calvo M, Stephan JL, Sarnacki S, Chevret S, Fromont C, de Coene C, le Deist F, Guy-Grand D, Fischer A: Attenuation of graft-versus-host disease and graft rejection by ex-vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 1994, 83:288-298. Murine model in which donor-anti-host activity is selectively depleted in vitro by treating host-activated donor T cells with a toxin-conjugated antibody to the CD25 activation marker. This maneuver successfully reduced GVHD in a haploidentical murine model.
62. Datta AR, Jiang YZ, Guimaraes A, Mardigal A, Van Rhee F, Barrett AJ: Distinct T-cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994, 14:517-524. In vitro model of "functional depletion" in humans. Donor-versus-myeloid leukemia reacting T cells can be spared when donor anti-host lymphocyte reactions are removed by killing host-activated donor cells with a ricin-conjugated anti-CD25.
63. Falkenberg JHF, Faber LM, van der Elshout M, van Luxemburg-Heijs SAP, Hooftman den Otter A, Smit WM, Boogt PJ, Willemz R: Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunotherapy 1993, 14:305-309.
64. Harris DT: In vitro and in vivo asessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 1995, 15:17-23. Cord blood transplantations may confer greater and more selective GVL reactivity than bone marrow or peripheral blood transplantations.
65. Jones R, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991, 77:649-653.
66. Kwak LW, Taib DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345:1016-1020. The strategy of donor vaccination to increase the anti-malignant T-cell response is likely to be increasingly used. However, the limitation of the present approach is that it has not been confirmed that donor T cells responding to myeloma protein idiotype also exert an anti-myeloma effect.
67. Hess AD, Jones RC, Santos GW: Autologous graft-versus-host disease: mechanism and potential therapeutic effect. Bone Marrow Transplant 1993, 12:S65-S69.
68. Benyunes MC, Thompson JA, York A, Buckner CD, Fefer A: Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancy. Prog Clin Biologic Res 1994, 389:229-238.
69. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A: Immunotherapy with interleukin-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995, 16:283-288. Pilot study showing that lymphokine-activated killer cells can be safely administered after autologous BMT and may confer an anti-lymphoma effect.